3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neoplasms
2
Solid Tumors
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Cancers
1
Interventions
Gemcitabine
5
Paclitaxel
4
Nivolumab
3
cobimetinib
2
atezolizumab
2
adavosertib
2
Ramucirumab
2
N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
2
Carboplatin
2
zansecimab
1
tocilizumab
1
tivozanib
1
tislelizumab
1
temsirolimus
1
ridaforolimus
1
plocabulin
1
pexidartinib
1
pevonedistat
1
pembrolizumab
1
pamiparib
1
obinutuzumab
1
necitumumab
1
liposomal doxorubicin
1
lenvatinib
1
glasdegib
1
futuximab
1
demplatin pegraglumer
1
birinapant
1
avelumab
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumors
×
ridaforolimus
×
Clear all
NCT01431534
2019-03-01
MK-8669-056
Merck Sharp & Dohme LLC
Phase 1
Terminated
20 enrolled
10 charts